Prediction of Anthracycline-Induced Left Ventricular Dysfunction by Cardiac Troponins

被引:4
|
作者
Thigpen, S. Calvin
Geraci, Stephen A.
机构
[1] Univ Mississippi, Sch Med, Dept Med, Div Hematol & Oncol, Jackson, MS 39216 USA
[2] Univ Mississippi, Sch Med, Dept Med, Div Cardiovasc Dis, Jackson, MS 39216 USA
关键词
anthracycline; chemotherapy; heart failure; troponin; HIGH-DOSE CHEMOTHERAPY; PEGYLATED LIPOSOMAL DOXORUBICIN; INDUCED CARDIOTOXICITY; CANCER-PATIENTS; LYMPHOMA; MARKER; ADULTS;
D O I
10.1097/SMJ.0b013e3182749006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Evidence suggests prognostic utility of troponin (Tn) serum concentrations for a variety of conditions. We sought to determine whether elevated concentrations early after anthracycline chemotherapy predict the development of left ventricular systolic dysfunction in adult patients with cancer. PubMed/MEDLINE searches identified original reports that assessed cardiac TnI or TnT within 5 days of anthracycline chemotherapy and evaluated left ventricular systolic function after treatment for review. Ten reports qualified for review. Four studies indicated a significant relation between elevated Tn and subsequent left ventricular systolic dysfunction. One study that enrolled patients actively receiving anthracyclines and others who had previously received anthracyclines also demonstrated a significant relation. The remaining five reports identified no such relation. Heterogeneity in experimental methods, sampling times, and handling of confounders was significant between positive and negative studies. The present evidence is insufficient to suggest that Tns are reliable predictors of left ventricular dysfunction in patients with cancer. These data suggest, however, that larger prospective studies using frequent scheduled Tn measurement with adjustment for confounding factors could determine the predictive value of Tns in this setting.
引用
收藏
页码:659 / 664
页数:6
相关论文
共 50 条
  • [31] Anthracycline-induced acute myocarditis and ventricular fibrillation arrest
    Pallazola, Vincent A.
    Murray, Joseph C.
    Al Harthy, Munjid
    Zimmerman, Stefan L.
    Webster, Jonathan
    Gondek, Lukasz P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) : 469 - 470
  • [32] Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma
    Nakayama, Takafumi
    Oshima, Yoshiko
    Shintani, Yasuhiro
    Yamamoto, Junki
    Yokoi, Masashi
    Ito, Tsuyoshi
    Wakami, Kazuaki
    Kitada, Shuichi
    Goto, Toshihiko
    Hashimoto, Hiroya
    Kusumoto, Shigeru
    Sugiura, Tomonori
    Iida, Shinsuke
    Seo, Yoshihiro
    CIRCULATION REPORTS, 2022, 4 (04) : 173 - 182
  • [33] Case report and review of the literature: the utilisation of a ventricular assist device as bridge to recovery for anthracycline-induced ventricular dysfunction
    Krasnopero, Diane
    Asante-Korang, Alfred
    Jacobs, Jeffrey
    Stapleton, Stacie
    Carapellucci, Jennifer
    Dotson, Mathew
    Stapleton, Gary
    CARDIOLOGY IN THE YOUNG, 2018, 28 (03) : 471 - 475
  • [34] Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity
    Ohtani, Kisho
    Fujino, Takeo
    Ide, Tomomi
    Funakoshi, Kouta
    Sakamoto, Ichirou
    Hiasa, Ken-ichi
    Higo, Taiki
    Kamezaki, Kenjiro
    Akashi, Koichi
    Tsutsui, Hiroyuki
    CLINICAL RESEARCH IN CARDIOLOGY, 2019, 108 (06) : 600 - 611
  • [35] ANTHRACYCLINE-INDUCED ALTERATIONS IN CARDIAC ACTIN SYNTHESIS INVITRO
    LEWIS, W
    GONZALEZ, B
    LABORATORY INVESTIGATION, 1986, 54 (01) : A36 - A36
  • [36] Microcirculation injury is involved in anthracycline-induced cardiac toxicity
    Galan, C.
    Vilchez-Tschischke, J. P.
    Lobo-Gonzalez, M.
    Lopez, G. J.
    Gavilan, M.
    De Molina-Iracheta, A.
    Perez-Martinez, C.
    Villena-Gutierrez, R.
    Oliver, E.
    Fernandez-Jimenez, R.
    Pizarro, G.
    Fuster, V.
    Sanchez-Gonzalez, J.
    Ibanez, B.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1878 - 1878
  • [37] Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity
    Kisho Ohtani
    Takeo Fujino
    Tomomi Ide
    Kouta Funakoshi
    Ichirou Sakamoto
    Ken-ichi Hiasa
    Taiki Higo
    Kenjiro Kamezaki
    Koichi Akashi
    Hiroyuki Tsutsui
    Clinical Research in Cardiology, 2019, 108 : 600 - 611
  • [38] The diagnosis of anthracycline-induced cardiac damage and heart failure
    Dudka, Jaroslaw
    Burdan, Franciszek
    Korga, Agnieszka
    Dyndor, Katarzyna
    Syroka, Iwona
    Zieba, Justyna
    Lewkowicz, Dorota
    Korobowicz-Markiewicz, Agnieszka
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2009, 63 : 225 - 233
  • [39] Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment
    Fabiani, Iacopo
    Chianca, Michela
    Cipolla, Carlo Maria
    Cardinale, Daniela Maria
    NATURE REVIEWS CARDIOLOGY, 2025,
  • [40] Anthracycline-Induced Dysfunction of Cardiac SR Ca2+ Handling - The Role of Thiol Oxidation
    Hanna, Amy D.
    Lam, Alex
    Dulhunty, Angela F.
    Beard, Nicole A.
    BIOPHYSICAL JOURNAL, 2013, 104 (02) : 106A - 107A